All In Biotech

NDA 211843 · Mission Pharmacal

Thiola Ec

Tiopronin · Oral · Reducing and Complexing Thiol

Orphan

Last checked: Nov 20, 2026Latest source record: Mar 8, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jun 28, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

0 Phase 3, 0 recruiting

FAERS reports

900

341 serious, 53 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 7, 2025.

THIOLA EC is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone. THIOLA EC is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone. ( 1 )

Mechanism: The goal of therapy is to reduce urinary cystine concentration below its solubility limit. Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronin-cysteine. From this reaction, a water-soluble mixed disulfide is formed and the amount of sparingly soluble cystine is reduced.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • THIOLA EC · TIOPRONIN 100MG · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
  • THIOLA EC · TIOPRONIN 300MG · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tiopronin" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective286
  • fatigue49
  • pyrexia48
  • rash48
  • nausea45
  • product dose omission issue36
  • vomiting30
  • flank pain26
  • proteinuria26
  • urinary tract infection26
  • diarrhoea23
  • dyspepsia21

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20054
20071
20081
20091
20106
201133
201234
20134
20141
20151
20167
20171
20181
201923
202036
202164
2022134
2023132
2024147
2025181
202686

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Thiola EC (Tiopronin)

2024 spending

$26.6M

Beneficiaries

285

3,028 claims

Per beneficiary

$93,242

$75.85 per unit

View as table
YearSpending
2020$18,792,840
2021$21,278,094
2022$21,868,127
2023$23,230,085
2024$26,573,882

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 38 on PubMed

Sponsor: Mission Pharmacal

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.